抗癌药物市场－全球产业规模、份额、趋势、机会和预测，按适应症、药物、给药途径、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球抗癌药物市场规模为1,799.3亿美元，预计2030年将以5.25%的复合年增长率成长至2,445.9亿美元。抗癌药物是专门用于抑製或摧毁恶性细胞的药物，是各种癌症治疗策略的基石。市场扩张的主要驱动因素包括全球癌症发生率的不断攀升、易患肿瘤疾病的老龄人口的增加，以及医学研究的持续进步带来的新型治疗突破。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球抗癌药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症分类（乳癌、血液癌症、摄护腺癌、胃肠道癌症、妇科癌症、肺癌、其他）
  • 依药物分类（细胞毒性药物、荷尔蒙疗法、标靶治疗、其他）
  • 依给药途径（口服、注射、其他）
  • 按最终使用者（医院和诊所、门诊中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美抗癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲抗癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区抗癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲抗癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲抗癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球抗癌药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Eli Lilly and Company (India) Pvt. Ltd.
• AstraZeneca plc
• Sanofi SA
• Bayer AG

第十六章：策略建议

第17章调查会社について・免责事项

The Global Anticancer Drug Market, valued at USD 179.93 Billion in 2024, is projected to experience a CAGR of 5.25% to reach USD 244.59 Billion by 2030. Anticancer drugs represent pharmaceutical agents specifically formulated to inhibit or destroy malignant cells, serving as the cornerstone for various cancer treatment strategies. The market's expansion is primarily driven by the escalating global incidence of cancer, an expanding aging population predisposed to oncological diseases, and continuous advancements in medical research that foster novel therapeutic breakthroughs.

Key Market Drivers

The increasing global cancer incidence substantially propels the anticancer drug market. A growing patient population naturally leads to a higher demand for diagnostic tools and subsequent therapeutic interventions, from chemotherapy to advanced targeted therapies. This demographic shift intensifies the need for a continuous supply of effective pharmaceuticals, driving companies to expand their portfolios. According to the International Agency for Research on Cancer, in 2022, there were an estimated 20 million new cancer cases worldwide, indicating a vast and expanding patient pool requiring treatment. The persistent rise in various cancer types underscores the demand for innovative drug solutions.

Key Market Challenges

A significant challenge impeding the growth of the global anticancer drug market is the considerable cost associated with the development and provision of advanced therapies. These high costs directly restrict patient access and affordability, particularly within emerging economies. This limitation reduces the eligible patient population for novel treatments, thereby hampering market penetration and overall sales volumes globally.

Key Market Trends

The integration of artificial intelligence (AI) in oncology is profoundly reshaping drug discovery and development processes. AI algorithms can analyze vast datasets, identify novel drug targets, and predict compound efficacy with increased speed and accuracy compared to traditional methods. This technological advancement significantly reduces the time and cost associated with bringing new anticancer drugs to market, fostering a more efficient and productive pipeline. According to Silicon Valley Bank, biotech AI attracted $5.6 billion in 2024, constituting nearly 30% of healthcare startup funding, reflecting a substantial increase driven by significant investment deals. This influx of capital underscores the industry's confidence in AI's transformative potential. For example, Insilico Medicine announced in June 2023 that its small molecule inhibitor drug candidate, INS018_055, an entirely AI-discovered and AI-designed drug, entered a phase 2 clinical trial for idiopathic pulmonary fibrosis, demonstrating the tangible progress of AI in therapeutic advancement.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Eli Lilly and Company (India) Pvt. Ltd.
• AstraZeneca plc
• Sanofi S.A.
• Bayer AG

Report Scope:

In this report, the Global Anticancer Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anticancer Drug Market, By Indication:

• Breast Cancer
• Blood Cancer
• Prostate Cancer
• Gastrointestinal Cancer
• Gynaecologic Cancer
• Lung Cancer
• Others

Anticancer Drug Market, By Drug:

• Cytotoxics
• Hormonal Therapy
• Targeted Therapy
• Others

Anticancer Drug Market, By Route of Administration:

• Oral
• Parenteral
• Others

Anticancer Drug Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Anticancer Drug Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anticancer Drug Market.

Available Customizations:

Global Anticancer Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anticancer Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Lung Cancer, Others)
  • 5.2.2. By Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Anticancer Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Drug
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anticancer Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Drug
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Anticancer Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Drug
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Anticancer Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Drug
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Anticancer Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Drug
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anticancer Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Drug
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. France Anticancer Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Drug
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Anticancer Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Drug
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Anticancer Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Drug
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Anticancer Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Drug
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia Pacific Anticancer Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Drug
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anticancer Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Drug
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Anticancer Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Drug
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Anticancer Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Drug
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Anticancer Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Drug
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Anticancer Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Drug
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. Middle East & Africa Anticancer Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Drug
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anticancer Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Drug
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Anticancer Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Drug
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Anticancer Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Drug
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Anticancer Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Drug
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anticancer Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Drug
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Anticancer Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Drug
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Anticancer Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Drug
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anticancer Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Genentech, Inc.
• 15.3. Novartis AG
• 15.4. Pfizer Inc.
• 15.5. Bristol-Myers Squibb Company
• 15.6. GlaxoSmithKline plc.
• 15.7. Eli Lilly and Company (India) Pvt. Ltd.
• 15.8. AstraZeneca plc
• 15.9. Sanofi S.A.
• 15.10. Bayer AG

16. Strategic Recommendations

17. About Us & Disclaimer